专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017205432A1 FUNCTIONALIZED PYRANO[2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE 审中-公开
标题翻译：功能化的吡喃并[2,3-d]嘧啶-7-酮衍生物及其制备和使用方法
公开(公告)号：WO2017205432A1
公开(公告)日：2017-11-30
申请号：PCT/US2017/034082
申请日：2017-05-23
申请人： LU, Dai , QIAO, Chang-Jiang , FU, Boqiao , DUDDUPUDI, Anantha, Lakshmi , WU, Zhixing
发明人： LU, Dai , QIAO, Chang-Jiang , FU, Boqiao , DUDDUPUDI, Anantha, Lakshmi , WU, Zhixing
IPC分类号： C07D471/04
CPC分类号： C07D491/052
摘要： Functionalized pyrano[2,3-d]pyrimidin-7-one derivatives, methods for making the derivatives, and methods of using the derivatives as protein kinase inhibitors.
摘要翻译：功能化的吡喃并[2,3-d]嘧啶-7-酮衍生物，制备该衍生物的方法，以及使用该衍生物作为蛋白激酶抑制剂的方法。

2. 发明申请

WO2011149921A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS 审中-公开
标题翻译：可溶性葡萄糖循环激活剂
公开(公告)号：WO2011149921A1
公开(公告)日：2011-12-01
申请号：PCT/US2011/037718
申请日：2011-05-24
申请人： MERCK SHARP & DOHME CORP. , RAGHAVAN, Subharekha , STELMACH, John, E. , SMITH, Cameron, J. , LI, Hong , WHITEHEAD, Alan , WADDELL, Sherman, T. , CHEN, Yi-Heng , MIAO, Shouwu , ORNOSKI, Olga, A. , GARFUNKLE, Joie , LIAO, Xibin , CHANG, Jiang , HAN, Xiaoqing , GUO, Jian , GROEPER, Jonathan, A. , BROCKUNIER, Linda, L. , ROSAUER, Keith , PARMEE, Emma, R.
发明人： RAGHAVAN, Subharekha , STELMACH, John, E. , SMITH, Cameron, J. , LI, Hong , WHITEHEAD, Alan , WADDELL, Sherman, T. , CHEN, Yi-Heng , MIAO, Shouwu , ORNOSKI, Olga, A. , GARFUNKLE, Joie , LIAO, Xibin , CHANG, Jiang , HAN, Xiaoqing , GUO, Jian , GROEPER, Jonathan, A. , BROCKUNIER, Linda, L. , ROSAUER, Keith , PARMEE, Emma, R.
IPC分类号： A01N43/90 , A61K31/519
CPC分类号： C07D487/04 , A61K31/519 , C07D519/00
摘要： A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：式（I）的化合物或其药学上可接受的盐能够调节身体的环磷酸鸟苷（“cGMP”）的产生，并且通常适用于治疗和预防与受干扰的cGMP平衡相关的疾病。本发明还涉及用于制备式I化合物或其药学上可接受的盐的方法，用于治疗和预防上述疾病和用于制备用于此目的的药物以及包含式（III）化合物的药物制剂 I）或其药学上可接受的盐。

3. 发明申请

WO2006118554A1 A DEGRADABLE, MACROPOROUS BIOACTIVE GLASS SCAFFOLD AS WELL AS ITS PREPARATION AND MANUFACTURING METHODS 审中-公开
标题翻译：作为其制备和制造方法，可降解的，大面积的生物玻璃SCAFFOLD
公开(公告)号：WO2006118554A1
公开(公告)日：2006-11-09
申请号：PCT/US2005/009769
申请日：2005-05-02
申请人： SHANGHAI INSTITUTE OF CERAMICS , CHANG, Jiang , GU, Weiming , ZHONG, Jipin
发明人： CHANG, Jiang , GU, Weiming , ZHONG, Jipin
IPC分类号： A61F2/02
CPC分类号： A61L27/58 , A61L27/10 , A61L27/56 , C03C3/062 , C03C3/097 , C03C4/0007 , C03C4/0014 , C03C11/00 , C03C12/00 , C03C14/00
摘要： This invention involves a fabrication method for a resorbable porous bioactive glass scaffold in biomaterial field. The characteristic of the glass scaffold in composition are 24-45 wt % of CaO, 34-50wt % of SiO2, 0-25wt % Na2O, 5-17wt % Of P2O5, 0-5wt % MgO and 0-lwt % of CaF2; 40-80 % in porosity; and 50-600µm in pore diameter. The method used melt-derived bioactive glass powders, and mixed with organic polymer with various particle sizes as a pore-maker. Then, the mixture will be dry-pressed or solution-injected into molds to become a green body. The green body is sintered at certain temperature to become a resorbable porous bioactive glass scaffold with a certain mechanic strength, adjustable porosity, and inter-connected pore size. This scaffold was reacted in a simulated body fluid and demonstrated a formation of hydroxyapatite on its surface, which means it is bioactive. This scaffold can be used as a bone graft material to repair the damaged tissue and as a cell culture scaffold to grow bone tissue in vitro.
摘要翻译：本发明涉及生物材料领域中可再吸收的多孔生物活性玻璃支架的制造方法。组合物中玻璃支架的特征是CaO为24-45wt％，SiO：34-50wt％，Na2O为0-25wt％，P2O5为5-17wt％，MgO为0-5wt％，CaF2为0-1wt％。 40-80％孔隙度; 孔径为50-600μm。该方法使用熔体衍生的生物活性玻璃粉末，并与各种粒径的有机聚合物作为造孔剂混合。然后，混合物将被干压或溶液注入模具成为一个绿色的身体。生坯在一定温度下烧结，成为具有一定机械强度，可调节孔隙率和相互连接孔径的可再吸收的多孔生物活性玻璃支架。该支架在模拟体液中反应，并在其表面上显示羟基磷灰石的形成，这意味着它是生物活性的。该支架可用作骨移植材料，以修复受损组织和作为细胞培养支架体外生长骨组织。

4. 发明申请

WO2006053014A2 SELECTIVE INHIBITION OF ROCK1 IN CARDIAC THERAPY 审中-公开
标题翻译：选择性抑制心脏病治疗中的ROCK1
公开(公告)号：WO2006053014A2
公开(公告)日：2006-05-18
申请号：PCT/US2005/040529
申请日：2005-11-09
申请人： BAYLOR COLLEGE OF MEDICINE , WEI, Lei , SCHWARTZ, Robert, J. , CHANG, Jiang , ENTMAN, Mark
发明人： WEI, Lei , SCHWARTZ, Robert, J. , CHANG, Jiang , ENTMAN, Mark
IPC分类号： A61K38/17 , A61K48/00
CPC分类号： A61K38/45 , A01K67/0276 , A01K2217/072 , A01K2217/075 , A01K2227/105 , A01K2267/0375 , A61K48/005 , A61K48/0058 , C07K14/4747 , C12N15/1137 , C12N15/86 , C12N2310/11 , C12N2310/14 , C12N2710/10343 , C12N2830/002
摘要： The present invention is directed to the treatment and/or prevention of disease as it relates to Rho kinase. In specific embodiments, disease is treated and/or prevented through the administration of an agent that selectively inhibits ROCK1. In specific embodiments, it inhibits ROCK1 and not ROCK2. In other specific embodiments, the disease is cardiac disease.
摘要翻译：本发明涉及与Rho激酶相关的疾病的治疗和/或预防。在具体实施方案中，通过施用选择性抑制ROCK1的药剂治疗和/或预防疾病。在具体实施方案中，其抑制ROCK1而不是ROCK2。在其他具体实施方案中，该疾病是心脏病。

5. 发明申请

WO2004064763A2 CLEAVAGE OF SERUM RESPONSE FACTOR IN CARDIAC DIAGNOSIS AND THERAPY 审中-公开
标题翻译：血清反应因子在心脏诊断和治疗中的清除
公开(公告)号：WO2004064763A2
公开(公告)日：2004-08-05
申请号：PCT/US2004/001736
申请日：2004-01-22
申请人： BAYLOR COLLEGE OF MEDICINE , SCHWARTZ, Robert, J. , WEI, Lei , CHANG, Jiang , ENTMAN, Mark
发明人： SCHWARTZ, Robert, J. , WEI, Lei , CHANG, Jiang , ENTMAN, Mark
IPC分类号： A61K
CPC分类号： A61K35/76 , A61K31/23 , A61K38/1709 , A61K38/25 , A61K38/27 , A61K38/30 , A61K38/45 , A61K48/005 , C07K16/18 , G01N33/6893 , G01N2800/32 , G01N2800/325
摘要： The present invention is directed to the cleavage of serum response factor as it relates to cardiac disease. In specific embodiments, failing cardiac tissue is diagnosed in tissues comprising elevated cleavage of serum response factor. In further specific embodiments, heart failure is associated with cardiac myocyte apoptosis as a result of an increase in cleaved serum response factor, particularly by caspases.
摘要翻译：本发明涉及与心脏病相关的血清反应因子的切割。在具体实施方案中，在包括升高的血清反应因子切割的组织中诊断出失败的心脏组织。在另外的具体实施方案中，由于切割的血清反应因子，特别是胱天蛋白酶增加，心力衰竭与心肌细胞凋亡相关。

6. 发明申请

WO2007111864A3 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE 审中-公开
公开(公告)号：WO2007111864A3
公开(公告)日：2008-10-02
申请号：PCT/US2007006806
申请日：2007-03-19
申请人： MERCK & CO INC , KIM RONALD M , PARMEE EMMA R , TAN QIANG , LINS ASHLEY ROUSE , CHANG JIANG , YANG CANGMING
发明人： KIM RONALD M , PARMEE EMMA R , TAN QIANG , LINS ASHLEY ROUSE , CHANG JIANG , YANG CANGMING
IPC分类号： A61K31/47 , C07D263/02 , C07D311/00 , C07D401/00
CPC分类号： C07D215/06 , C07C229/52 , C07C233/83 , C07C235/42 , C07C255/57 , C07C309/65 , C07C309/66 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D209/10 , C07D213/30 , C07D213/56 , C07D213/61 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D215/20 , C07D215/227 , C07D231/12 , C07D231/56 , C07D235/18 , C07D239/34 , C07D257/06 , C07D261/08 , C07D263/57 , C07D271/10 , C07D271/12 , C07D277/64 , C07D277/68 , C07D285/14 , C07D307/42 , C07D307/79 , C07D307/81 , C07D311/12 , C07D311/58 , C07D333/54 , C07D333/60 , C07D401/04 , C07D405/04 , C07D409/04 , C07D417/12 , C07D491/04
摘要： Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

7. 发明申请

WO2007111864A2 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE 审中-公开
标题翻译： GLUCAGON受体拮抗剂化合物，包含这些化合物的组合物和使用方法
公开(公告)号：WO2007111864A2
公开(公告)日：2007-10-04
申请号：PCT/US2007/006806
申请日：2007-03-19
申请人： MERCK & CO., INC. , KIM, Ronald, M. , PARMEE, Emma, R. , TAN, Qiang , LINS, Ashley Rouse , CHANG, Jiang , YANG, Cangming
发明人： KIM, Ronald, M. , PARMEE, Emma, R. , TAN, Qiang , LINS, Ashley Rouse , CHANG, Jiang , YANG, Cangming
IPC分类号： A61K31/47
CPC分类号： C07D215/06 , C07C229/52 , C07C233/83 , C07C235/42 , C07C255/57 , C07C309/65 , C07C309/66 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D209/10 , C07D213/30 , C07D213/56 , C07D213/61 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D215/20 , C07D215/227 , C07D231/12 , C07D231/56 , C07D235/18 , C07D239/34 , C07D257/06 , C07D261/08 , C07D263/57 , C07D271/10 , C07D271/12 , C07D277/64 , C07D277/68 , C07D285/14 , C07D307/42 , C07D307/79 , C07D307/81 , C07D311/12 , C07D311/58 , C07D333/54 , C07D333/60 , C07D401/04 , C07D405/04 , C07D409/04 , C07D417/12 , C07D491/04
摘要： Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
摘要翻译：公开了胰高血糖素受体拮抗剂化合物。该化合物可用于治疗2型糖尿病及相关病症。还包括药物组合物和治疗方法。

8. 发明申请

WO2004064763A3 CLEAVAGE OF SERUM RESPONSE FACTOR IN CARDIAC DIAGNOSIS AND THERAPY 审中-公开
标题翻译：血清反应因子在心脏诊断和治疗中的清除
公开(公告)号：WO2004064763A3
公开(公告)日：2007-08-16
申请号：PCT/US2004001736
申请日：2004-01-22
申请人： BAYLOR COLLEGE MEDICINE , SCHWARTZ ROBERT J , WEI LEI , CHANG JIANG , ENTMAN MARK
发明人： SCHWARTZ ROBERT J , WEI LEI , CHANG JIANG , ENTMAN MARK
IPC分类号： A61K38/18 , A61K20060101 , A61K35/76 , A61K38/25 , A61K38/27 , A61K38/30 , A61K48/00 , C07K16/18
CPC分类号： A61K35/76 , A61K31/23 , A61K38/1709 , A61K38/25 , A61K38/27 , A61K38/30 , A61K38/45 , A61K48/005 , C07K16/18 , G01N33/6893 , G01N2800/32 , G01N2800/325
摘要： The present invention is directed to the cleavage of serum response factor as it relates to cardiac disease. In specific embodiments, failing cardiac tissue is diagnosed in tissues comprising elevated cleavage of serum response factor. In further specific embodiments, heart failure is associated with cardiac myocyte apoptosis as a result of an increase in cleaved serum response factor, particularly by caspases.
摘要翻译：本发明涉及与心脏病相关的血清反应因子的切割。在具体实施方案中，在包括升高的血清反应因子切割的组织中诊断出失败的心脏组织。在另外的具体实施方案中，由于切割的血清反应因子，特别是胱天蛋白酶增加，心力衰竭与心肌细胞凋亡相关。

9. 发明申请

WO2012062157A1 PYRANO[3,2-D]THIAZOL DERIVATIVES AND USES THEREOF AS SELECTIVE GLYCOSIDASE INHIBITORS 审中-公开
标题翻译： PYRANO [3,2-D]噻唑衍生物及其作为选择性糖苷酶抑制剂的用途
公开(公告)号：WO2012062157A1
公开(公告)日：2012-05-18
申请号：PCT/CN2011/080691
申请日：2011-10-12
申请人： ALECTOS THERAPEUTICS INC. , MERCK SHARP & DOHME CORP. , CHANG, Jiang , LIU, Kun , MCEACHERN, Ernest J. , MU, Changwei , SELNICK, Harold G. , SHI, Feng , VOCADLO, David J. , WANG, Yaode , WEI, Zhongyong , ZHOU, Yuanxi , ZHU, Yongbao
发明人： CHANG, Jiang , LIU, Kun , MCEACHERN, Ernest J. , MU, Changwei , SELNICK, Harold G. , SHI, Feng , VOCADLO, David J. , WANG, Yaode , WEI, Zhongyong , ZHOU, Yuanxi , ZHU, Yongbao
IPC分类号： C07D513/04 , A61K31/429 , A61P29/00 , A61P25/28 , A61P37/08 , A61P9/00
CPC分类号： C07D513/04
摘要： Pyrano[3,2-d]thiazol derivatives of formula (I) for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds are disclosed. Methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc are also provided.
摘要翻译：公开了用于选择性抑制糖苷酶的式（I）的吡喃并[3,2-d]噻唑衍生物，该化合物的用途和包括该化合物的药物组合物。还提供了治疗与O-GlcNAcase的缺乏或过度表达相关的疾病和障碍的方法，O-GlcNAc的积累或缺乏。

10. 发明申请

WO2009114374A3 I/Q IMBALANCE ESTIMATION USING SYNCHRONIZATION SIGNALS IN LTE SYSTEMS 审中-公开
标题翻译： I / Q在LTE系统中使用同步信号的不平等估计
公开(公告)号：WO2009114374A3
公开(公告)日：2010-02-25
申请号：PCT/US2009036125
申请日：2009-03-05
申请人： INTERDIGITAL PATENT HOLDINGS , HAGHIGHAT AFSHIN , NAYEB NAZAR SHAHROKH , CHANG JIANG , LU I-TAI , KOO CHANG-SOO
发明人： HAGHIGHAT AFSHIN , NAYEB NAZAR SHAHROKH , CHANG JIANG , LU I-TAI , KOO CHANG-SOO
IPC分类号： H04L27/26 , H04L25/02 , H04L27/00
CPC分类号： H04L27/2647 , H04J11/0069 , H04L25/022 , H04L25/0228 , H04L2027/0016 , H04L2027/0024
摘要： A method and apparatus perform I/Q imbalance estimation and compensation using synchronization signals in LTE systems. Primary and secondary synchronization signals (P-SCH and S-SCH), which carry synchronization information, are embedded in each LTE frame, and are used for receiver I/Q imbalance estimation. Additionally, the performance may be significantly improved by optimally selecting the training data in I/Q imbalance estimation.
摘要翻译：一种方法和装置使用LTE系统中的同步信号来执行I / Q不平衡估计和补偿。携带同步信息的主同步信号（P-SCH和S-SCH）嵌入在每个LTE帧中，并用于接收机I / Q不平衡估计。另外，通过最佳地选择I / Q不平衡估计中的训练数据可以显着提高性能。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式